Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update Authors: Luca Zagaroli, Alessio Di Berardino, Francesco Petragnano, Serena Lustri, Irene Fasciani, Mario Rossi, Marco G Baroni, Maurizio Delvecchio Published: 2026 ABSTRACT AbstractIntroductionMaturity-onset diabetes of the young (MODY) is a rare monogenic form of diabetes characterized by impaired insulin secretion and genetic and clinical heterogeneity. Accurate molecular diagnosis enables precision medicine by guiding gene-specific treatment, improving glycemic control, and avoiding unnecessary therapies. Since our previous systematic review in 2020, new studies have further clarified therapeutic strategies and emerging treatment options. This review updates the evidence on pharmacological management of MODY and its clinical implications.MethodsA systematic review was conducted following PRISMA 2020 recommendations. PubMed was searched for studies published between April 2020 and October 2025. Eligible studies included individuals with genetically confirmed MODY receiving pharmacological treatment, therapeutic switches, or adjunctive therapies. Data were extracted and synthesized qualitatively due to heterogeneity in study design and outcome reporting.ResultsNinety-one studies were included. Strong evidence confirms sulfonylureas (SUs) as first-line therapy in Hepatocyte Nuclear Factor 1A (HNF1A)-, Hepatocyte Nuclear Factor 4A (HNF4A)-, ATP-binding cassette transporter sub-family C member 8 (ABCC8)-, and potassium inwardly rectifying channel subfamily J member 11 (KCNJ11)-MODY, frequently enabling improved glycemic control and transition from insulin. Glucokinase (GCK)-MODY remains managed without pharmacological treatment outside pregnancy, but dorzagliatin, a novel agent acting as a glucokinase activator, may further expand precision treatment approaches. Insulin remains the mainstay of treatment in Hepatocyte Nuclear Factor 1B (HNF1B)- and Insulin (INS)-MODY, although adjunctive therapies may provide benefits. While SUs are supported by consistent observational evidence, the role of incretin-based therapies and sodium-glucose co-transporter 2 inhibitors remains exploratory, largely based on small studies and case reports.ConclusionsA major limitation of the available evidence is the predominance of small, heterogeneous observational studies, which limits the strength and generalizability of therapeutic recommendations. Recent literature largely confirms existing genotype-guided treatment recommendations while suggesting expanded therapeutic options for selected MODY subtypes. Precision medicine based on molecular diagnosis remains essential for optimal management.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13300-026-01884-2.Keywords: Maturity-onset diabetes of the young (MODY), Monogenic diabetes, Precision medicine, Sulfonylureas, Genotype-guided therapy, Hepatocyte nuclear factor 1A (HNF1A)-MODY, Hepatocyte nuclear factor 4A (HNF4A)-MODY, Glucokinase (GCK)-MODY, Incretin-based therapies, Sodium-glucose co-transporter 2 (SGLT2) inhibitors Key Summary Points Maturity-onset diabetes of the young (MODY) is a paradigmatic example of precision medicine, in which molecular diagnosis enables genotype-guided therapy and optimization of clinical management.Sulfonylureas remain the first-line pharmacological treatment for several MODY subtypes, particularly.Hepatocyte Nuclear Factor 1A (HNF1A)-, Hepatocyte Nuclear Factor 4A (HNF4A)-, ATP-binding cassette transporter sub-family C member 8 (ABCC8)-, and potassium inwardly rectifying channel subfamily J member 11 (KCNJ11)-MODY, often allowing transition from insulin with improved glycemic control.Glucokinase (GCK)-MODY usually requires no pharmacological treatment outside pregnancy, emphasizing the importance of genetic diagnosis to avoid unnecessary lifelong therapy.Recent evidence highlights the potential role of incretin-based therapies and sodium-glucose co-transporter inhibitors as adjunctive treatments in selected patients with progressive β-cell dysfunction or insulin resistance.Most available evidence derives from observational studies, underscoring the need for international collaborative research and prospective trials to strengthen genotype-guided treatment strategies. Introduction Maturity-onset diabetes of the young (MODY) is a rare monogenic form of diabetes that accounts for approximately 1–6% of children and adolescents with diabetes [1, 2]. A genotype-first approach has confirmed that MODY variants were present in 1 in 1052 individuals and accounted for 1.48% of diabetes cases diagnosed before age 40 [3]. It encompasses clinically and genetically heterogeneous disorders caused by single-gene defects that impair β-cell function and lead to mild to severe insulin deficiency. MODY is a paradigmatic setting for precision medicine: a confirmed molecular diagnosis can guide glucose-monitoring, avoid unnecessary therapies (e.g., insulin when not indicated), and inform gene-specific treatment, genetic counseling, and prognosis [4]. Although an onset before 25 years of age has traditionally been considered, increasing evidence shows that diagnosis may occur later. Historically, up to 14 MODY subtypes were described, although most cases arise from variants in Hepatocyte Nuclear Factor 1A (HNF1A), Glucokinase (GCK), and Hepatocyte Nuclear Factor 4A (HNF4A) genes, with prevalence differing across cohorts [5–8]. Phenotype can vary to some extent among carriers of the same variant and even within the same pedigree. Subtypes differ by age at onset, genotype, glycemic patterns, and extra-pancreatic features -such as renal cysts in Hepatocyte Nuclear Factor 1B (HNF1B)-MODY or neonatal hypoglycemia and macrosomia in HNF4A-MODY. Accurate molecular diagnosis is linked to better outcomes by enabling gene-tailored therapy, mitigation of complication risk, targeted family counseling, and reduction of stigma associated with inappropriate treatment. The importance of accurate diagnosis and treatment adjustment has been outlined by numerous authors and international guidelines [2, 9], even if trial evidence is limited. The risk of micro- and macrovascular complications relates to the degree and duration of hyperglycemia and not to the etiology of the disease. As a result, achieving glycemic targets reduces the onset and progression of vascular complications [10, 11]. Advances in genetic testing, particularly next-generation sequencing, have improved diagnostic accuracy and reduced misclassification as type 1 (T1D) or type 2 (T2D) diabetes, improving recognition and management of monogenic diabetes. The patient’s perspective reported by Thanabalasingham et al. [12] is meaningful to understand the difficulties in some settings to properly diagnose monogenic diabetes and provide the appropriate treatment, and the patients’ thoughts. It highlights how an etiological diagnosis improves quality of life and blood glucose control. The increasing number of diagnoses has raised clinical awareness of this condition, emphasizing the need for targeted therapeutic approaches within the framework of precision medicine. In this context, research on monogenic diabetes has expanded in recent years, with several relevant studies investigating potential pharmacological treatment strategies for these patients. In 2020, we published a review summarizing gene-specific treatment evidence for clinicians [13]. Therefore, 5 years later, we undertook a comprehensive revision of the review to incorporate emerging evidence from the scientific literature, focusing on practical implications for the precision treatment of monogenic diabetes. Materials and Methods Study Design We conducted a systematic review in accordance with PRISMA 2020 recommendations (qualitative synthesis; no meta-analysis planned a priori). We searched PubMed for studies published from April 16, 2020 (date of the last study included in the previous review [13]) to October 11, 2025 (search last run on October 11, 2025). The full search string was: ((mody[Title/Abstract]) OR (maturity-onset diabetes of the young[Title/Abstract]) OR (HNF4A[Title/Abstract]) OR (GCK[Title/Abstract]) OR (HNF1A[Title/Abstract]) OR (Pancreatic and Duodenal Homeobox 1 -PDX1- [Title/Abstract]) OR (HNF1B[Title/Abstract]) OR (Neurogenic Differentiation 1 -NEUROD1-[Title/Abstract]) OR (Krüppel-like factor 11 -KLF11-[Title/Abstract]) OR (Carboxyl Ester Lipase -CEL-[Title/Abstract]) OR (Paired Box 4 -PAX4-[Title/Abstract]) OR (Insulin –INS-[Title/Abstract]) OR (B-Lymphocyte Kinase -BLK-[Title/Abstract]) OR (ATP-binding cassette transporter sub-family C member 8 -ABCC8-[Title/Abstract]) OR (potassium inwardly rectifying channel subfamily J member 11 -KCNJ11-[Title/Abstract]) OR (adapter protein containing PH domain -APPL1-[Title/Abstract])) AND ((treatment[Title/Abstract]) OR (therapy[Title/Abstract])). PubMed was selected as the primary database for its extensive coverage of the biomedical literature. To minimize missing studies, we also manually screened the reference lists of included articles, identifying additional relevant publications. This approach was consistent with the search strategy adopted in our previously published systematic review [13], in order to ensure methodological continuity and comparability between the original review and the present update. The selection of articles was conducted according to the PICOS framework as follows: Population: individuals with genetically confirmed MODY (any subtype), children or adults. Population: individuals with genetically confirmed MODY (any subtype), children or adults. Intervention/Exposure: any antihyperglycemic treatment or therapy modification after genetic diagnosis with reported outcomes. Intervention/Exposure: any antihyperglycemic treatment or therapy modification after genetic diagnosis with reported outcomes. Comparators: any (including within-patient before/after) or none for single-arm/case designs. Comparators: any (including within-patient before/after) or none for single-arm/case designs. Outcomes: glycemic outcomes (e.g., hemoglobin A1c -HbA1c-, continuous glucose monitoring -CGM- metrics), hypoglycemia, weight or body mass index (BMI), tolerability/adverse events, pregnancy outcomes, and explicit post-genetic switches (e.g., from insulin to sulfonylurea -SU-). Outcomes: glycemic outcomes (e.g., hemoglobin A1c -HbA1c-, continuous glucose monitoring -CGM- metrics), hypoglycemia, weight or body mass index (BMI), tolerability/adverse events, pregnancy outcomes, and explicit post-genetic switches (e.g., from insulin to sulfonylurea -SU-). Eligibility Criteria For this review, we included only peer-reviewed original studies (trials, cohorts, case series, case reports). Papers were eligible if the diagnosis of MODY was genetically confirmed, the treatment was defined, and outcomes were clearly reported. Additional papers were identified by a manual search of the references from the retrieved articles. Conference abstracts without full text, reviews/editorials/guidelines papers, papers without clearly reported outcomes or insufficient/fragmented data precluding extraction, and non-English language manuscripts were excluded. This review uses only previously published data and does not include research involving human participants or animals conducted by the authors. Two reviewers (LZ, MD) independently screened titles/abstracts and full texts; disagreements were resolved by consensus. Using a piloted template, we collected: first author, year, country, study design, genetic test, MODY gene/variant, sample size, age/sex where available, treatment(s) and post-genetic therapy changes, and outcomes (HbA1c and other clinical endpoints). When multiple time points were reported, pre/post values related to therapy changes were extracted. Outcomes and Synthesis The primary objective of this paper is to provide an update about gene-specific treatment management by summarizing therapeutic responses and outcomes. The methodological quality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS). Given the inclusion of case reports and case series, quality assessment was interpreted descriptively across study designs. The quality assessment results are displayed in the supplementary material, Tables 1–14. Protocol and Deviations The methodological framework was consistent with that used in the previously published review. To further ensure transparency, the protocol for this updated review has now been registered in the PROSPERO database (registration number CRD420261328522). Methods followed those of the prior review [13], with an extended time window to October 11, 2025. Final PRISMA counts (records identified/removed/excluded/included) and any additional studies retrieved in the last search will be reported in the Results and the PRISMA flow-chart. The PRISMA 2020 checklist is provided as supplementary material (Table 15). Study Selection The initial search yielded 3856 records. After removal of duplicates, 3783 titles/abstracts were screened, and 3426 records were excluded for not meeting the inclusion criteria. Of 357 full-text articles assessed, 272 were excluded (topic not fully relevant, neonatal diabetes, therapy not specified or not evaluable). Six additional studies were identified through reference list screening. In total, 91 studies met all inclusion criteria and were included in the qualitative synthesis (Fig. 1). PRISMA flow-chart To avoid excessive length of the manuscript, and given the lack of meaningful novelty in the pathophysiology over the last year, we do not describe in this paper the genetic defects and the pathophysiological effects, reported in our previous paper [13], but just a brief clinical presentation of each MODY subtype. This article is based on previously conducted studies and does not contain new studies with human participants or animals performed by any of the authors. HNF4A-MODY (Supplementary Material, Table 1) Individuals with HNF4A-MODY usually have normal or near-normal glucose tolerance in the first decade of life. Glucose intolerance typically emerges in adolescence/early adulthood alongside hormonal changes that increase insulin resistance. In early disease, when fasting glucose and HbA1c remain in the non-diabetic range, moderating dietary carbohydrate can reduce post-prandial excursions. Over time, HbA1c tends to rise, while ketosis remains uncommon owing to preserved endogenous insulin secretion. When lifestyle alone is insufficient, SUs in this genotype, often outperform insulin as first-line therapy [2]. SUs bind Sulfonylurea Receptor 1 (SUR1) subunit, closing the potassium ATP-sensitive (KATP) channel, depolarizing the β-cell membrane and promoting insulin [14, 15]. Current guidance emphasizes the high SU sensitivity of HNF4A-MODY and supports SUs as preferred initial pharmacotherapy when feasible [2]. Switches to SUs. Beyond earlier reports [16–19], additional case-based papers describe late reclassification to HNF4A-MODY with transition from insulin to low-dose SU (gliclazide/glipizide), improving HbA1c and CGM metrics [20–22]. Across case series and observational studies, switching from insulin to SUs consistently improves glycemic control (HbA1c 6–7%) in patients initially misdiagnosed with T1D or T2D [20–25]. Efficacy and durability of SUs. A recent HNF4A-MODY series documented clinically meaningful HbA1c reductions on SU monotherapy, with durable control during follow-up; adjunct agents such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter inhibitors (SGLT2i) were used when BMI was higher, diabetes was longer-standing, or insulin secretory capacity was reduced [26]. In particular, in this large series (31 patients), 51.6% of the patients showed a significant reduction in HbA1c (p = 0.045) during SU treatment with stable glycemic control after 6 years of follow-up (IQR: 3.5–11). The remaining 48.4% of patients required additional therapies, such as insulin, presenting a higher BMI (p = 0.037) and a longer duration of diabetes (p = 0.03) [26]. The authors conclude that patients on just SU (mean dose 120 mg/day) were younger (p = 0.011) and presented a shorter history of dysglycemia (p = 0.019). Alternatives or add-on to SUs. Two descriptive case series of four patients, two treated with GLP-1 RAs and two with dual gastric inhibitory peptide (GIP)/GLP-1 RAs [27], and two patients, treated with GLP-1 RAs [28], showed that these agents are effective to enable down-titration or even withdrawal of insulin or other oral hypoglycemic agents (OHAs). HbA1c decreased by 0.6–1.8% reaching the therapeutic target, BMI decreased by 1.4–5 kg/m2 and 7.4–10.4 kg/m2 in patients on GLP-1 RAs and dual GIP/GLP-1 RAs, respectively, with overall good tolerability [26]. Larger improvement (HbA1c − 2.5% and − 3.7%) was reported by Broome et al. [28]. Similar data were reported by Crowley et al. [26] in three patients treated with GLP1-RAs who showed an HbA1c decrease from 76 mmol/mol to 58 mmol/mol and a meaningful weight reduction. Even SGLT2i were shown to be effective in two patients from the same cohort, despite an increased risk of genital-urinary infection. GCK-MODY (Supplementary Material, Table 2) GCK-MODY is the most frequent subtype of MODY worldwide. It is characterized by mild, stable hyperglycemia since birth. In our previous review, the studies supported no pharmacologic therapy for individuals with GCK-MODY [13], and more recent reports are in line with previous conclusions. In the majority of patients, diet and physical exercise are sufficient to manage mild hyperglycemia with HbA1c only slightly above the normal range [19, 29–31]. Excluding pregnancy studies, we identified 208 individuals with GCK-MODY: 157 were managed with diet/exercise, 17 received no therapy, 30 were on OHAs (most commonly metformin, n = 12), and 11 were on insulin, which was discontinued after genetic confirmation in most of them [18, 29–40]. Studies consistently show that GCK-MODY is characterized by mild, stable hyperglycemia at diagnosis (fasting glucose ~ 125 mg/dl, mean HbA1c around 6–7%). Most patients maintain adequate glycemic control with diet and lifestyle measures alone, while the addition of insulin or oral glucose-lowering agents (metformin, SU, GLP-1 RA, SGLT2i) provide little or no additional benefit and are often discontinued after genetic confirmation. These findings are consistent across adult and pediatric case series, cohorts, and registries, supporting early molecular diagnosis and minimal-intervention management [8, 21–24, 29, 30, 40–44]. This new evidence reinforces the “no routine drugs” principle outside pregnancy and confirms that in these subjects the molecular diagnosis prevents unnecessary medication. Pregnancy Pregnancy is a special context of increased insulin resistance and requires gene-aware management. In a registry analysis of 54 women and 128 pregnancies, 39 insulin-treated gestations were associated with adverse events (hypoglycemia in 22 pregnancies, including nine severe), whereas no adverse events were reported in untreated gestations. Among mutation-positive fetuses, maternal insulin treatment was associated with lower birthweight than non-insulin management; among mutation-negative fetuses, birthweight did not differ between treated and untreated pregnancies [46]. In a similar study of 34 women, 59% of pregnancies were managed with diet and 41% with insulin: in GCK-unaffected offspring, cesarean section rate, birthweight and large for gestational age (LGA) prevalence were higher than in GCK-affected offspring. This is because the fetus, not inheriting the mutation, perceives maternal blood glucose as “too high”, thus increases insulin secretion and the risk of macrosomia. Insulin during pregnancy did not reduce LGA in unaffected offspring and was associated with earlier gestational age and more cesarean sections, with no effect on birthweight in affected offspring [47]. A prospective series of 41 GCK-MODY pregnancies compared insulin (n = 21) vs. diet (n = 20): hypoglycemia occurred in a substantial fraction of offspring in the insulin group, whereas no hypoglycemia or perinatal complications were reported among offspring from non-insulin pregnancies; birthweight was lower in GCK-affected newborns when mothers received insulin than when they did not, whereas unaffected neonates had higher birthweight and 33% were macrosomic [48]. Contemporary single-case reports illustrate how CGM can support diet-only management in most GCK-MODY pregnancies, with time-in-range improving across gestation and no increase in maternal hypoglycemia or neonatal complications in a pregnant woman from China [49]. Familial GCK-MODY reports similarly emphasize that, outside pregnancy, pharmacological therapy is generally unnecessary and that intrapartum insulin should be reserved for suspected non-carrier fetuses with overgrowth [24, 25, 45]. A novel oral hypoglycemic agent, dorzagliatin provides proof-of-concept for precision treatment in GCK-MODY. It is a first-in-class dual-acting glucokinase activator approved in China for the treatment of adults with T2D. It restores glucose sensitivity in pancreatic β-cells and enhances hepatic glucose utilization, thereby targeting a fundamental defect in glucose homeostasis. In a double-blind randomized placebo-controlled crossover study, eight adults with GCK-MODY (7F/1 M; age 36.1 ± 6.4 years; HbA1c 6.7 ± 0.3%) underwent a 2-h hyperglycemic clamp after a single 75 mg oral dose. Dorzagliatin lowered basal glucose versus placebo (4.6 ± 0.6 vs. 5.4 ± 0.3 mmol/l) and significantly improved second-phase insulin secretion and β-cell glucose sensitivity, with no serious adverse events (one mild hypoglycemia treated with i.v. dextrose). In an 8-year follow-up case report, dorzagliatin 75 mg twice daily reduced HbA1c from 7.4 to 6.3% at 3 months and 6.1% at 6 months, with no hypoglycemic events reported [50, 51]. HNF1A-MODY (Supplementary Material, Table 3) HNF1A-MODY typically presents in adolescence or early adulthood with progressive hyperglycemia in non-obese, autoantibody-negative individuals. A key feature is a reduced renal threshold for glucose reabsorption, leading to glycosuria at relatively low plasma glucose levels. Glycemia often shows normal or mildly elevated fasting glucose initially, with early post-prandial hyperglycemia, followed by a gradual deterioration over time. Microvascular complications may occur; therefore, carbohydrate-moderated nutrition and early SUs therapy are recommended [2]. In early disease, satisfactory control has been reported with dietary intervention alone in some carriers [29, 32, 36]. A recent Turkish pediatric MODY cohort also reported four HNF1A-MODY cases mainly managed with diet or metformin rather than sulfonylureas, highlighting heterogeneous real-world treatment patterns [42]. As disease progresses, SUs are highly effective and often provide better glycemic control than insulin, even in pediatric cases [52]. Dosing should start low (about one-quarter of typical starting doses) and can often be maintained at low maintenance doses (e.g., gliclazide 20–40 mg/day) [53, 54]. Interestingly, some recent papers explore the safety and efficacy of other OHAs in the treatment of these patients. The superiority of SU-based therapy has been confirmed by multiple studies and case series; after genetic diagnosis, switch to SU improves glycemic control [18, 38, 55–60]. Durable, low-dose SU regimens have been reported in adolescents and young adults with sustained HbA1c between 5.5 and 6.9% on glibenclamide/glimepiride, sometimes after initial insulin exposure [48, 61, 62]. A structured switch program showed benefit across pathogenic HNF1A variants and, in 6/9 with likely-pathogenic/variant of unknown significance (VUS), despite prior insulin use; non-responders often had absent endogenous insulin or T2D criteria [63]. Similar findings were reported in other ancestries [64–66]. The GLIMLINA study, a randomized, double-blind, crossover trial, investigated the effect of linagliptin add-on to glimepiride (vs. placebo add-on) on fasting glucose, glycemic variability, and HbA1c [68]. The authors randomly assigned 19 adult patients (HbA1c 7.4 ± 6 0.2% [57.1 ± 7.3 mmol/mol]) to treatment with glimepiride and linagliptin 5 mg for 16 weeks, 4-week washout, and then glimepiride and placebo for 16 weeks [or vice versa). They found that glimepiride + linagliptin did not significantly improve the mean amplitude of glycemic excursions (MAGE) as compared to glimepiride and placebo, but significantly reduced the coefficient of variation on CGM, the HbA1c (without any difference in hypoglycemic events), the glimepiride dose, and finally improved the beta-cell glucose sensitivity. Repaglinide has been effective in SU-intolerant patients, improving HbA1c when other agents failed [69]. Adding a SGLT2i to gliclazide + metformin improved glycemia and enabled dose reduction of other OHAs in poorly controlled patients [47, 70]. The efficacy of SGLT2i was evaluated by Maagensen et al. [71] in a randomized, 25 mg empagliflozin versus placebo double-blind study, through a crossover two three-step hyperglycemic clamps targeted at 1-h periods of 10, 14, and 18 mmol/l glucose in 11 adult patients with MODY and ten with T2D. The similar effect on urinary glucose excretion between the two groups (urinary glucose excretion in the patients with MODY 24.5 g, 95% CI 20.6–28.3), indicates that SGLT2i as a potential treatment option. Small mechanistic and clinical studies also suggest a useful adjunctive role for SGLT2i in HNF1A-MODY: empagliflozin produced comparable increases in glucosuria in HNF1A-MODY and in T2D during a hyperglycemic clamp, without genotype-specific safety signals in this small sample [72], and single-patient reports have documented HbA1c and weight benefits with SGLT2i either before or after genetic confirmation [73, 74]. A detailed case report of newly diagnosed HNF1A-MODY after euglycemic diabetic ketoacidosis on dapagliflozin described a practical sequence: post-resolution control with basal/bolus insulin, then de-intensification to gliclazide 30 mg/day + linagliptin 5 mg/day after genetic confirmation, with HbA1c improving from 10.2 to 6.3%, reinforcing SU sensitivity and cautious use of SGLT2i in undifferentiated young-onset diabetes [73]. Contemporary case series/reports extend the mutational and phenotypic spectrum, further supporting a precision-medicine approach [74, 75]. Multi-gene pediatric and adult cohorts and registry analyses likewise show that, after molecular diagnosis, many individuals with HNF1A-MODY can be managed with low-dose SUs or other oral agents with good glycemic control and progressive de-escalation of insulin, while newer injectable agents such as GLP-1 RAs or dual GIP/GLP-1 agonists may further improve HbA1c and weight in selected individuals [23, 27, 41–44, 76]. Combined use of insulin and OHAs may be appropriate in some cases to optimize blood glucose control [77]. PDX1-MODY (Supplementary Material, Table 4) PDX1-MODY is phenotypically heterogeneous and presents in adolescence or early adulthood with mild to moderate hyperglycemia. The disease course is slowly progressive, reflecting impaired insulin secretion rather than insulin resistance. Some mutation carriers may also show subtle exocrine pancreatic dysfunction or a family history of early-onset diabetes. Contemporary population-based genetic data show that treatment ranges from diet/OHAs to insulin when needed [44, 78, 79], supporting a precision-medicine approach anchored in molecular diagnosis, phenotype, and treatment response. Management is individualized, starting with medical nutrition therapy and physical activity. Low-dose SUs can be effective in selected cases (e.g., sustained control with gliclazide in a 28-year-old man) [80]. Dipeptidyl peptidase-4 (DPP-4) inhibitors may help address post-prandial hyperglycemia: an 18-year-old maintained HbA1c between 6.0 and 6.5% first on gliclazide 40 mg/day, then on sitagliptin 50 mg/day. His father carried the same variant but achieved HbA1c 6.3–6.5% with diet alone [81]. Metformin may be reasonable when there is evidence of insulin resistance. In one patient with HbA1c 13.6%, it reduced HbA1c to < 7%, and later insulin add-on restored control when HbA1c rose again [82]. In the Diabetes Patienten Verlaufsdokumentation (DPV) registry, 13 patients with PDX1-MODY (38.5% with positive anti beta-cell antibodies) showed good overall glycemic control, with mean HbA1c 6.0% in the first year after diagnosis and 6.5% at last visit, a median daily insulin dose of 0.6 IU/kg, and a heterogeneous treatment pattern including insulin therapy in 30.8%, OHA/GLP-1-based therapy in 38.5%, metformin in 15.4%, glinides in 15.4%, SUs in 15.4%, and lifestyle-only management in 38.5% [76]. HNF1B-MODY (Supplementary Material, Table 5) HNF1B-MODY is characterized by early-onset diabetes with variable hyperglycemia, often requiring insulin early due to impaired insulin secretion. It is frequently associated with renal abnormalities (cysts), hypomagnesemia, and urogenital or liver involvement. Diabetes progression is heterogeneous and reflects a multisystem disorder rather than isolated β-cell dysfunction. The treatment of patients with HNF1B-MODY has often been challenging, as responses to the proposed therapeutic approaches have been highly variable. Recent series advocate insulin as first-line in many cases, confirming previous data and reporting good control when used early and tailored to individual renal/metabolic status [83–88]. A Brazilian case report highlighted the difficulty of control (HbA1c 12.1%) despite therapy with very high insulin requirements (1.7 IU/kg/day) [89]. GLP-1 RAs are increasingly reported as insulin-sparing options [90]. A 17-year-old reduced multiple daily insulin dose from 1.0 to 0.4 IU/kg/day after switching to semaglutide 0.5 mg weekly, with HbA1c falling from 7.0% to 5.9%, time in range (TIR) rising from 70 to 88% and time below range (TBR) decreasing from 5 to 1%. The treatment was stopped at 4 months for gastrointestinal adverse effects [91]. In another report, liraglutide added to basal insulin rapidly improved TIR (from 39 to 65% in 6 days) and maintained HbA1c < 7% on continued therapy [92]. A further report in a patient showed HbA1c and weight benefits with GLP-1 RAs or dual GIP/GLP-1 RAs [27]. These observations indicate that the GLP-1 RAs may be used as adjuncts or temporary alternatives in HNF1B-MODY when weight, variability or hypoglycemia are concerns, recognizing that tolerability and durability may limit long-term use and that insulin often remains necessary. NEUROD1-MODY (Supplementary Material, Table 6) NEUROD1-MODY has a variable age of onset, from childhood to adulthood. It is caused by impaired β-cell differentiation and insulin secretion with heterogeneous severity, ranging from mild hyperglycemia to insulin-requiring diabetes. Incomplete penetrance is described and clinical expression is heterogeneous, even within families, and as a result not all carriers develop diabetes [93, 94]. When hyperglycemia occurs, medical nutrition therapy is foundational. OHAs can be effective in a substantial subset, approximately half in published series/reviews, often as monotherapy or dual therapy (e.g., SUs, metformin, DPP-4 inhibitors) [94]. Insulin should be used when glycemic targets are not achieved with OHAs or when β-cell dysfunction is advanced. In a recent nationwide Japanese cohort, Yoshiji et al. identified only one adolescent with NEUROD1-MODY (diagnosed at 15 years, HbA1c 6.9%) among 67 carriers of pathogenic or likely pathogenic MODY variants, and individual treatment details were not reported, underscoring how rare and poorly characterized this subtype remains [44]. An illustrative report described a 48-year-old misdiagnosed as T2D who failed multiple non-insulin agents and ultimately required basal insulin to achieve HbA1c around 7.5%, underscoring variable drug responsiveness in NEUROD1-MODY [95]. KLF11-MODY (Supplementary Material, Table 7) The clinical evidence base is sparse and heterogeneous, and reported pedigrees show phenotypes overlapping other diabetes forms [96, 97]. Presentations span from early-onset insulin-treated diabetes to milder dysglycemia manageable with OHAs. Insulin has often been started early in published cases [96]. Conversely, metformin-based management can suffice in selected carriers: Zhang et al. reported a proband whose HbA1c improved from 9.5% to 6% with metformin plus diet. The patient’s mother and grandmother (both KLF11 carriers) were also maintained on metformin [97]. Given the rarity and variability, therapy should be individualized after genetic confirmation, with periodic reassessment of progression and treatment response. Additional cohort and registry data provide a more granular picture of KLF11-related diabetes. In a Turkish pediatric MODY cohort (n = 44) including a broad spectrum of genes, two KLF11 mutation carriers (4.5%) were identified; one was treated with insulin from diagnosis and the other started on metformin before requiring insulin, against a background of markedly elevated HbA1c in non-GCK subtypes (mean 9.48 ± 3.75%) and frequent use of combined OHAs and insulin [42]. In the DPV registry, KLF11-MODY remained rare but showed relatively high treatment intensity, with all carriers on insulin therapy, mean HbA1c decreasing from 7.6% in the first year to 7.2% at last visit, and one-third also receiving metformin and 16.7% an SGLT2i, while no use of SUs, GLP-1 RAs or other OHAs was reported [76]. CEL-MODY (Supplementary Material, Table 8) Diabetes usually develops in the third to fourth decade, frequently in association with pancreatic cysts [98]. In early or mild hyperglycemia, diet and exercise can be sufficient for glycemic control in selected individuals [29]. When pharmacotherapy is required, available reports suggest that insulin is often the most appropriate option, such as in the case report by Kondoh et al. who described excellent control (HbA1c 5.5%) with 0.5 IU/kg/day of insulin [99]. Given the limited evidence base, therapy should be individualized and guided by longitudinal assessment of glycemia and exocrine pancreatic involvement [98–100]. In a Turkish pediatric cohort, four CEL mutation carriers were identified, with one managed on diet alone, one on insulin only, and two requiring combined metformin plus insulin [42]. PAX4-MODY (Supplementary Material, Table 9) Reported presentations range from childhood to adult onset, with variable severity, from diet-controlled or OHA-treated hyperglycemia to insulin-requiring diabetes. In consideration of the rarity of the disease, the treatment experience is limited. In a large Brazilian cohort (14 carriers), outcomes were heterogeneous: some remained untreated with HbA1c 5.1–5.5%, one maintained control on diet alone, others used unspecified OHAs with divergent results (HbA1c 11.3% vs. 6.0%), and three required multiple daily injections (MDI) (HbA1c 9.6% and 7.4%; one not available) [89]. A 19-month-old boy achieved adequate control on MDI, illustrating that early insulin may be required in pediatric presentations [101]. INS-MODY (Supplementary Material, Table 10) INS-MODY is caused by a defective insulin production or processing. It presents with variable age of onset, from childhood to early adulthood, and progressive hyperglycemia due to β-cell dysfunction. Short-term benefit from medical nutrition therapy and, in selected cases, OHAs may occur, but many individuals ultimately require insulin therapy as β-cell function progressively declines [102, 103]. In the paper by Schlegel et al., intensifying from metformin + basal glargine to include rapid-acting aspart improved HbA1c from 10.6 to 6.9% in 3 months [104]. In selected insulin-treated cases, adjunct therapy can assist. Empagliflozin (25 mg/day) as add on treatment to MDI showed to be effective decreasing HbA1c from 18.6 to 8.6% in a 17-year-old boy [105]. A recent case report described an adolescent who initially required high-dose insulin + metformin. After 2.5 years and weight loss, metabolic control normalized and pharmacotherapy (insulin and metformin) was discontinued, highlighting phenotypic variability and the possibility of de-intensification in selected scenarios [106]. Pediatric and adult multi-gene cohorts indicate that many individuals are managed with insulin from diagnosis, but that non-insulin agents such as metformin, SUs, or GLP-1 RAs are sometimes used as adjuncts or in milder phenotypes [23, 41, 43, 44, 76]. Cohort and registry data provide additional granularity. In a Chinese pediatric program, six patients with INS-MODY were mostly managed with long-term insulin, with individual examples showing HbA1c improving from 10.8 to 6.6%, from 8.3 to 6.5%, from 14.5 to 6.4%, from 12.0 to 8.5%, and from 15.3 to 6.8%, while one case worsened from 8.9 to 11.3% [41]. In the DPV registry, INS-MODY remained rare but treatment was intensive, with mean HbA1c 6.9% in the first year and 7.2% at last visit, 71.4% receiving insulin therapy, 28.6% having OHA/GLP-1-based treatment (including 14.3% on SUs and 14.3% on GLP-1 RAs) and 28.6% recorded as lifestyle therapy [76]. Similarly, in a Chinese single-center series, six of seven patients with INS-MODY remained on insulin and one on metformin after genetic diagnosis, despite many other non-GCK MODY cases being able to discontinue insulin [43]. BLK-MODY (Supplementary Material, Table 11) In these patients, glycemic derangement is variable. While many patients ultimately require insulin, some can be managed with medical nutrition therapy and/or OHAs, particularly early in the disease course or in milder phenotypes [107]. Given limited evidence and variable penetrance, treatment should be individualized after genetic confirmation, with attention to weight management and life-stage triggers (e.g., pregnancy). Pediatric cohorts provide further insight into BLK-related diabetes. In a Turkish cohort, 2 BLK mutation carriers were identified, with one managed on metformin and one on diet alone [42]. In a Chinese single-center series, one BLK-MODY child was treated with combined insulin and metformin after genetic diagnosis, suggesting that BLK-MODY often requires at least oral pharmacotherapy and may sometimes necessitate insulin [43]. ABCC8-MODY (Supplementary Material, Table 12) ABCC8-MODY presents with variable age of onset and severity, from mild hyperglycemia to overt diabetes [108] and risk of severe complications [109]. A key feature is marked sensitivity to SUs, which are often effective. Some mutations overlap with neonatal diabetes phenotypes, reflecting broad clinical heterogeneity. In line with guidelines, after genetic diagnosis, many individuals can be switched from insulin (or other OHAs) to SUs with significant improvement in glycemic control [110–117]. In a pediatric series, most carriers of ABCC8/KCNJ11 variants diagnosed in individuals younger than 3 years successfully transitioned from insulin to oral SUs with clinical benefit [118]. Case series also note that responses to SUs can be durable yet variable across individuals [109], and in some of them the dose requirements may decrease over time, occasionally allowing temporary discontinuation [119]. In selected mild presentations, dietary management alone has yielded satisfactory control [29, 120]. As a non-SU option, GLP-1 RAs have shown benefit in ABCC8-MODY, improving glycemia with weight loss and a low hypoglycemia risk [121]. KCNJ11-MODY (Supplementary Material, Table 13) The β-cell mechanism and the phenotype parallels ABCC8, as these genes encode for different subunits of the same channel. Most reports indicate that switching from insulin/OHAs to SU after genetic confirmation, with significantly improved glycemic outcomes [122–125]. In selected cases, diet-first approaches have maintained control without contraindications [29, 126]. Heterogeneous phenotypes are described, including presentations with systemic comorbidities (e.g., pituitary stalk interruption syndrome, liver disease) for which long-term glycemic follow-up has been limited in the literature [127]. During pregnancy, temporary re-introduction of insulin may be required. Re-challenge with glibenclamide in later trimesters has been reported without complications in carefully selected cases [124]. APPL1-MODY (Supplementary Material, Table 14) Reported pedigrees show adult-onset diabetes with autosomal-dominant transmission and variable severity. Diet, OHAs, and insulin have all been used, with treatment individualized to glycemic severity and progression. In two APPL1 families (24 carriers), seven required insulin, four were managed with diet alone, and two used OHAs [128]. In the Turkish pediatric cohort, a single APPL1-MODY case was identified: it was a 15.3-year-old lean boy with incidental hyperglycemia, a strong three-generation family history of diabetes, negative β-cell autoantibodies and a heterozygous APPL1 NM_012096.3:c.2018C > G (p.S673C) variant classified as VUS, managed with combined metformin and insulin [42]. Discussion This systematic review updates and expands the therapeutic landscape of MODY, highlighting relevant advances since our previous review [13]. While the central role of genotype-guided therapy remains unchanged, recent evidence provides important insights into treatment durability, adjunctive pharmacological options, and emerging precision therapies that may further refine individualized management. Table 1 summarizes some practical guidance for the therapeutic management of patients with MODY and has been developed to assist clinicians in clinical practice. In addition, given the variable strength of evidence across MODY subtypes, Table 1 was designed to provide readers with an overview of the available evidence and to facilitate interpretation of the therapeutic suggestions. Table 1Practical suggestions for managements of patients with MODYGenePractice-oriented notesStrength of evidenceHNF4ARecent evidence reinforces SUs as first-line treatment, with GLP-1-based therapies as reasonable alternatives or add-ons when SUs intolerance, hypoglycemia risk, or weight management considerations ariseInsulin is generally reserved for pregnancy (when indicated) or advanced β-cell failureModerate/consistentGCKRecent papers reinforce the suggestion to not treat these individuals with any hypoglycemic agentsPregnancy management should be guided by fetal genotype and growth: insulin is generally not indicated when the fetus is GCK-affected (risk of growth restriction) and may be considered when the fetus is unaffected and shows excess growth. When fetal genotype is unknown, early CGM can support a conservative, growth-aware prandial insulin approach, targeting the upper end of pregnancy glucose ranges and focusing on post-prandial control to curb macrosomia if the fetus is unaffected while avoiding over-tight control if affectedDorzagliatin, a GCK activator licensed for human use only in China, is an emerging option in GCK-MODY, supported by proof-of-concept clamp data showing improved second-phase insulin secretion and β-cell glucose sensitivity versus placebo with no serious adverse events, and by a case report describing HbA1c reduction after failure of multiple therapies with treatment reported as safe under biochemical monitoringModerate/consistent for conservative management; preliminary for dorzagliatinHNF1AStart with low-dose SU and titrate carefully; consider DPP-4 inhibitors as add-on to reduce variability or SU dose, repaglinide when SU are not tolerated, and SGLT2i or GLP-1-RA in selected scenarios (weight, hypoglycemia, cardio-renal risk), with insulin reserved for pregnancy when indicated or for advanced β-cell failureModerate/consistentPDX1Start with diet-first and weight-sensitive strategies; consider SU or DPP-4 inhibitor for post-prandial control. Use metformin when insulin resistance is present and insulin if targets are not met or β-cell function declinesPreliminary/case-basedHNF1BAnticipate reduced SU sensitivity and a lower threshold for insulin initiation. Manage comorbid kidney disease proactively; coordinate nephrology, hepatology, and lipid care. Consider GLP-1RA (and/or DPP-4 inhibitors) as adjuncts to reduce insulin dose, improve TIR and support weight control, monitoring for gastrointestinal adverse effects and reassessing need for insulin as disease progressesLimitedNEUROD1Start with diet/lifestyle, consider SU, metformin, or DPP-4 inhibitors based on phenotype and tolerability; escalate to insulin when neededPreliminary/case-basedKLF11Consider metformin (± lifestyle) in mild, stable hyperglycemia; use insulin when hyperglycemia is marked or progressivePreliminary/case-basedCELConsider lifestyle-only management in mild disease; escalate to insulin when targets are unmet or hyperglycemia progresses. Monitor exocrine function and pancreatic imaging features over time; management remains case-by-case given scarce treatment dataPreliminary/case-basedPAX4Start with medical nutrition therapy; consider OHA in mild, stable hyperglycemia; use insulin when targets are unmet or in more severe/early-onset phenotypesPreliminary/case-basedINSUse CGM-guided titration and early basal-bolus optimization; consider adjuncts selectively, with vigilance for euglycemic ketosis risk in insulin-deficient statesLimited; supported by broader neonatal diabetes evidenceBLKWhile many patients ultimately require insulin, some can be managed with medical nutrition therapy and/or OHAs, particularly early in the disease course or in milder phenotypes. Given limited evidence and variable penetrance, treatment should be individualized after genetic confirmation, with attention to weight management and life-stage triggers (e.g., pregnancy)Preliminary/case-basedABCC8Prioritize SU switch after molecular confirmation; monitor dose requirements and long-term durability. Consider GLP-1RA as adjuncts or alternatives when SU is poorly tolerated or weight loss is desirableLimited to moderate in MODY; supported by broader KATP-channel diabetes evidenceKCNJ11Expect substantial SU responsiveness after genetic diagnosis; titrate carefully to minimize hypoglycemia. Use diet/lifestyle in mild disease; reserve insulin for pregnancy, intercurrent illness, or inadequate SU response. Remain vigilant for neurological involvement in KCNJ11 disease and tailor counseling accordinglyLimited to moderate in MODY; supported by broader KATP-channel diabetes evidenceAPPL1Tailor therapy (diet/OHAs/insulin) to phenotype and progression; reassess periodically. Consider concomitant insulin-resistance pathways when selecting OHAs, given APPL1’s role in adiponectin-insulin signalingPreliminary/case-basedHNF4A hepatocyte nuclear factor 4α, GCK glucokinase, HNF1A hepatocyte nuclear factor 1α, PDX1 pancreatic and duodenal homeobox 1, HNF1B hepatocyte nuclear factor 1β, NEUROD1 neurogenic differentiation 1, KLF11 Kruppel-like factor 11, CEL carboxyl ester lipase, PAX4 paired box 4, INS insulin, BLK B lymphoid tyrosine kinase, ABCC8 ATP-binding cassette subfamily C member 8, KCNJ11 potassium inwardly-rectifying channel subfamily J member 11, SU sulfonylurea(s), GLP-1 RA glucagon-like peptide-1 receptor agonist(s), CGM continuous glucose monitoring, HbA1c hemoglobin A1c, DPP-4 dipeptidyl peptidase-4, SGLT2i sodium–glucose co-transporter-2 inhibitor(s), TIR time in range, OHA oral hypoglycemic agent, KATP potassium ATP-sensitive channel Practical suggestions for managements of patients with MODY Recent evidence reinforces SUs as first-line treatment, with GLP-1-based therapies as reasonable alternatives or add-ons when SUs intolerance, hypoglycemia risk, or weight management considerations arise Insulin is generally reserved for pregnancy (when indicated) or advanced β-cell failure Recent papers reinforce the suggestion to not treat these individuals with any hypoglycemic agents Pregnancy management should be guided by fetal genotype and growth: insulin is generally not indicated when the fetus is GCK-affected (risk of growth restriction) and may be considered when the fetus is unaffected and shows excess growth. When fetal genotype is unknown, early CGM can support a conservative, growth-aware prandial insulin approach, targeting the upper end of pregnancy glucose ranges and focusing on post-prandial control to curb macrosomia if the fetus is unaffected while avoiding over-tight control if affected Dorzagliatin, a GCK activator licensed for human use only in China, is an emerging option in GCK-MODY, supported by proof-of-concept clamp data showing improved second-phase insulin secretion and β-cell glucose sensitivity versus placebo with no serious adverse events, and by a case report describing HbA1c reduction after failure of multiple therapies with treatment reported as safe under biochemical monitoring HNF4A hepatocyte nuclear factor 4α, GCK glucokinase, HNF1A hepatocyte nuclear factor 1α, PDX1 pancreatic and duodenal homeobox 1, HNF1B hepatocyte nuclear factor 1β, NEUROD1 neurogenic differentiation 1, KLF11 Kruppel-like factor 11, CEL carboxyl ester lipase, PAX4 paired box 4, INS insulin, BLK B lymphoid tyrosine kinase, ABCC8 ATP-binding cassette subfamily C member 8, KCNJ11 potassium inwardly-rectifying channel subfamily J member 11, SU sulfonylurea(s), GLP-1 RA glucagon-like peptide-1 receptor agonist(s), CGM continuous glucose monitoring, HbA1c hemoglobin A1c, DPP-4 dipeptidyl peptidase-4, SGLT2i sodium–glucose co-transporter-2 inhibitor(s), TIR time in range, OHA oral hypoglycemic agent, KATP potassium ATP-sensitive channel Among the most extensively studied subtypes, HNF1A-MODY and HNF4A-MODY continue to demonstrate marked sensitivity to SUs, confirming their role as first-line pharmacological therapy [2, 18, 20–25, 38, 52, 55–60, 64–67]. However, recent data provide novel insights into predictors of long-term SU efficacy. Treatment durability appears strongly influenced by clinical and metabolic factors, including younger age at diagnosis, shorter diabetes duration, and preserved β-cell function [27, 52, 63, 67]. These findings reinforce the importance of early molecular diagnosis, as delayed identification may reduce the likelihood of sustained response to SU therapy. One randomized crossover trial, small observational studies, and case series indicate that incretin-based agents may represent useful adjunctive or alternative options in selected individuals with HNF1A- and HNF4A-MODY. Case series and observational studies have reported meaningful reductions in HbA1c and body weight, along with reduced insulin requirements or successful insulin discontinuation following initiation of GLP-1 RAs or dual GIP/GLP-1 RAs [23, 26, 27, 41–44, 76]. The GLIMLINA randomized crossover trial further demonstrated that linagliptin added to glimepiride improved glycemic variability, HbA1c, and β-cell glucose sensitivity without increasing hypoglycemia risk, indicating the potential role of incretin-based combination therapy in optimizing metabolic control [68]. These findings suggest that incretin-based agents may represent promising adjunctive therapies in selected individuals with progressive β-cell dysfunction or emerging insulin resistance, although evidence derives mainly from small studies and case-based reports. Similarly, emerging data suggest a possible adjunctive role for SGLT2i in selected patients; however, current evidence remains limited and should be interpreted with caution. Empagliflozin induces significant glucosuria and improves glycemic control in HNF1A-MODY, with effects comparable to those observed in T2D [71, 72]. Clinical reports also suggest benefits in HbA1c reduction, weight control, and treatment simplification when used alone or in combination with other agents [47, 70, 73, 74]. However, safety considerations, particularly the risk of diabetic ketoacidosis, require careful patient selection and monitoring [72]. These findings support a more flexible, phenotype-guided approach. Recent evidence also highlights therapeutic advances in HNF1B-MODY, a subtype traditionally characterized by early insulin dependence. While insulin remains the cornerstone of treatment [83–88], incretin-based therapies have shown promising insulin-sparing effects in selected cases. Case reports describe reductions in insulin requirements and improvements in glycemic control, TIR, and body weight following initiation of GLP-1 RAs [29, 89, 91], in line with our personal observation (unpublished data). These observations suggest a possible adjunctive role for incretin-based therapies in improving metabolic outcomes and reducing treatment burden, although evidence remains limited to case-based experience. For GCK-MODY, recent evidence largely confirms previous recommendations supporting conservative management without pharmacological therapy in most individuals [19, 29–45]. However, an important novel development is the emergence of glucokinase activators as potential precision therapies. Dorzagliatin, a dual-acting GCK activator currently approved in China for T2D, represents a promising targeted therapy, although current evidence remains limited to proof-of-concept data and case-level experience [50, 51]. While clinical experience remains limited, this agent represents a promising example of targeted therapy directly addressing the underlying molecular defect. Further studies are needed to clarify its long-term efficacy, safety, and applicability across diverse populations. In pregnancy, recent observational studies further refine genotype-driven management strategies. Evidence continues to support individualized treatment based on fetal genotype and growth patterns, with insulin therapy reserved for unaffected fetuses showing evidence of overgrowth [46–48]. In addition, advances in diabetes technologies, particularly continuous glucose monitoring, may provide valuable tools to optimize glycemic control while minimizing overtreatment and associated risks [49]. These developments contribute to a more personalized and physiologically appropriate management approach during pregnancy. Recent data suggest possible therapeutic applications for MODY subtypes associated with ABCC8 and KCNJ11 gene mutations. Consistent with previous knowledge, individuals with these mutations often exhibit marked SU sensitivity and can successfully transition from insulin to oral therapy following genetic diagnosis [110–117, 121–123]. Emerging evidence also suggests a potential adjunctive role for incretin-based therapies in selected cases, particularly when additional metabolic benefits such as weight reduction are desired [30, 118–120, 124]. Recent reports confirm that insulin therapy remains the mainstay of treatment for INS-MODY due to progressive β-cell dysfunction [102, 103], but emerging evidence suggests that adjunctive therapies, including metformin, SGLT2i, and incretin-based agents, may provide temporary metabolic benefits and facilitate treatment de-intensification in selected individuals [76, 104–106]. These observations highlight the phenotypic heterogeneity of INS-MODY and suggest that individualized therapeutic strategies may delay, but not prevent, eventual insulin dependence. We highlight that for ABCC8-, KCNJ11- and INS-MODY, the available MODY-specific evidence is relatively limited, although it is biologically and clinically supported by the more robust literature on neonatal diabetes. Evidence remains limited for rarer MODY subtypes associated with PDX1, NEUROD1, CEL, KLF11, PAX4, and APPL1 gene mutations. However, recent cohort and registry data reinforce the importance of individualized management based on clinical phenotype, typically involving lifestyle interventions, OHAs, and eventual insulin therapy as β-cell dysfunction progresses [42, 44, 76, 129, 130]. An additional contributor to clinical heterogeneity is represented by digenic inheritance, which may result in variable phenotypic expression and therapeutic response, further emphasizing the need for individualized treatment approaches guided by clinical and genetic characteristics [131]. Collectively, the most relevant therapeutic advances include the expanding role of incretin-based therapies as adjunctive treatments, the emergence of SGLT2i as potential add-on options, and the development of targeted therapies such as GCK activators. These innovations reflect a shift toward increasingly individualized and mechanism-based treatment strategies. Despite these advances, important limitations in the available evidence persist. Most therapeutic data derive from observational studies, case series, and small cohorts, with few randomized clinical trials. Furthermore, heterogeneity in study design, outcome measures, and follow-up duration limits the ability to establish definitive treatment algorithms for several subtypes. Taken together, all these factors result in limited robust evidence in the literature for several MODY subtypes. Nevertheless, the overall consistency of genotype-specific treatment responses across studies supports the validity of precision medicine approaches in MODY management. From a methodological point of view, it could be argued that a potential limitation of this review is that the literature search was conducted only in PubMed; however, this choice ensured methodological continuity with our previously published review, and manual screening of reference lists was performed to minimize the risk of missing relevant studies. Accordingly, the therapeutic suggestions reported in this review should be interpreted with caution, as the underlying strength of evidence varies substantially across MODY subtypes, ranging from relatively consistent data in some settings to limited or exploratory evidence in others. We believe that beyond diagnostic screening, systematic investigation of the molecular and cellular mechanisms underlying β-cell dysfunction in MODY is essential to identify novel therapeutic targets and further advance precision medicine in monogenic diabetes. Future research should prioritize prospective studies, randomized clinical trials, and international collaborative registries to strengthen the evidence base and refine treatment algorithms. Deeper investigation into the molecular mechanisms underlying β-cell dysfunction may identify novel, pathway-specific therapeutic targets and enable the development of more effective, mechanism-based treatments. Continued advances in molecular diagnostics and therapeutic development are expected to further improve individualized care and clinical outcomes in this heterogeneous group of patients, reinforcing the role of monogenic diabetes as a model for precision endocrinology. Conclusions Recent literature confirms knowledge on the therapeutic management of MODY and reinforces the current genotype–phenotype treatment recommendations. In particular, the central role of genotype-guided therapy, such as SUs in HNF1A-, HNF4A-, ABCC8-, and KCNJ11-MODY, and the conservative approach in GCK-MODY, is consistently supported by observational and clinical evidence. At the same time, emerging studies suggest potentially useful therapeutic options in selected patients. Evidence for newer therapeutic approaches (incretin-based therapies, SGLT2i, and GCK activators), which may offer additional benefits in selected patients and further expand the precision medicine approach, remains limited and heterogeneous. However, the strength of evidence differs substantially across MODY subtypes, being more consistent for sulfonylurea-based treatment in HNF1A-, HNF4A-, ABCC8-, and KCNJ11-related diabetes, and more limited or exploratory for newer adjunctive therapies and rarer subtypes. The low prevalence and heterogeneity of MODY are major barriers to conducting adequately powered trials. International collaborative efforts and multicenter registries will therefore be essential to increase sample sizes, strengthen the quality of evidence, and refine treatment recommendations. Hopefully, such initiatives will ultimately improve individualized care and support clinicians in optimizing therapeutic strategies for these rare but clinically important conditions. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 683 kb) Acknowledgments Medical Writing/Editorial Assistance ChatGPT (version 5.2) was used to check English grammar. No further medical writing / editorial assistance was required. The authors agree that the edits reflect their original work following the use of AI. We confirm that all authors take full responsibility for the content of the manuscript and approve the final version. Authors Contributions Luca Zagaroli, Alessio Di Berardino, Francesco Petragnano, Serena Lustri, Irene Fasciani, Mario Rossi, Marco Giorgio Baroni, Maurizio Delvecchio contributed to the study conception and design. All authors read and approved the final manuscript. Funding No funding or sponsorship was received for the publication of this article. Data Availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Declarations Conflict of Interest Luca Zagaroli, Alessio Di Berardino, Francesco Petragnano, Serena Lustri, Irene Fasciani, Mario Rossi, and Marco Giorgio Baroni do not declare any competing interests. Maurizio Delvecchio is an Editorial Board member of Diabetes Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ethical Approval This article is based on previously conducted studies and does not contain new studies with human participants or animals performed by any of the authors. Footnotes Prior Publication: This manuscript is not based on work that has been previously presented/published. References Associated Data Supplementary Materials Supplementary file1 (PDF 683 kb) Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.